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Antioxidants are currently used as efficient excipients that delay or inhibit the oxidation process of 
molecules. Excipients are often associated with adverse reactions. Stability studies can guide the search 
for solutions that minimize or delay the processes of degradation. The ability to predict oxidation 
reactions in different drugs is important. Methods: This study was conducted to assess the rational use 
of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium metabisulfite (SMB), 
propyl gallate (PG) and cysteine  (CYS) in tablet formulations of simvastatin and ketoconazole. These 
antioxidants were evaluated according to stability parameters and the relationship between efficiency 
of the antioxidant and chemical structure of the drugs. Results were compared with DPPH tests and 
computational simulations. BHT was most efficient regarding simvastatin stability, and the most effective 
BHT concentrations for maintaining stability were 0.5 and 0.1%. In relation to ketoconazole, SMB was 
most efficient for maintaining content and dissolution profile. The evaluation by DPPH showed that 
the largest percentage of absorbance reduction was observed for PG, while SMB proved most efficient 
and had lower consumption of DPPH. The same pattern was observed, albeit with lower efficiency, for 
the other lipophilic antioxidants such as BHT and BHA. The results of the molecular modeling study 
demonstrated that electronic properties obtained were correlated with antioxidant activity in solution, 
being useful for the rational development of liquid pharmaceutical formulations but not for solid oral 
formulations. This study demonstrated the importance of considering stability parameters and molecular 
modeling to elucidate the chemical phenomena involved in antioxidant activity, being useful for the 
rational use of antioxidants in the development of pharmaceutical formulations.
Uniterms: Antioxidants/rational use. Excipients/evaluation. Butylated hydroxyanisole/rational use. 
Butylated hydroxytoluene/rational use. Sodium metabisulfite/rational use. Propyl gallate/rational use. 
Cysteine/rational use. Simvastatin/tablets/evaluation. Ketoconazole/tablets/evaluation.
Atualmente, antioxidantes são usados como excipientes eficientes, que retardam ou inibem o processo 
de oxidação de moléculas. Excipientes são frequentemente associados a efeitos adversos. Estudos de 
estabilidade podem ajudar na busca por possíveis soluções para minimizar ou retardar os processos de 
degradação. A habilidade de prever as reações de oxidação em diferentes fármacos é importante. O estudo 
foi conduzido com o objetivo de avaliar o uso racional de hidroxianisol butilado (BHA), hidroxitolueno 
butilado (BHT), metabissulfito sódico (SMB), galato de propila (PG) e cisteína (CYS) em formulações 
de comprimidos de sinvastatina e cetoconazol. Eles foram avaliados por parâmetros de estabilidade e 
pela relação entre a eficiência dos antioxidantes e a estrutura química do fármaco. Os resultados foram 
comparados com testes de DPPH e simulações em computador. BHT foi mais eficiente com relação a 
estabilidade da sinvastatina e às concentrações mais eficientes para manutenção de estabilidade foram 
0,5 e 0,1%. Com relação ao cetoconazol, SMB foi mais eficiente em manter o conteúdo e o perfil de 
dissolução. A avaliação por DPPH mostrou que o maior percentual de redução de absorção foi observado 
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para PG, enquanto que SMB mostrou ser mais eficiente e consumir menos DPPH. A mesma tendência 
foi observada com menos eficiência em todos os outros antioxidantes lipofílicos como o BHT e BHA. 
Os resultados do estudo de modelagem molecular demonstraram que as propriedades eletrônicas obtidas 
podem ser correlacionadas com a atividade antioxidante em solução, sendo útil para o desenvolvimento 
racional de formulações farmacêuticas líquidas, mas não para formulações sólidas orais. Este estudo 
demonstrou a importância de considerar parâmetros de estabilidade e modelagem molecular para 
elucidar os fenômenos químicos envolvidos na atividade antioxidante, sendo úteis para o uso racional 
de antioxidantes no desenvolvimento de formulações farmacêuticas.
Unitermos: Antioxidantes/uso racional. Excipientes/avaliação. Hidroxianisol butilado/uso racional. 
Hidroxitolueno butilado/uso racional. Metabissulfito sódico/uso racional. Galato de propila/uso racional. 
Cisteína/uso racional. Sinvastatina/comprimidos/avaliação. Cetoconazol/comprimidos/avaliação.
INTRODUCTION
Excipients play a vital role in maintaining the ex-
pected pharmacological effect, modifying drug release 
rate and stability. More recently, they cannot be classi-
fied simply as diluents but also as a means of increasing 
weight, consistency and volume, and may even promote 
fast disintegration, dissolution and particularly stability 
(Pifferi, Restani, 2003).
The stage of formulation development in early 
pre-formulation studies assessing physical and chemical 
interactions, such as incompatibilities between an active 
pharmaceutical ingredient (API) and excipients of interest, 
has become relevant (Peres-Filho et al., 2011). Such incom-
patibilities may affect drug stability and bioavailability, in-
terfering with efficacy and safety (Rowland, Tozer, 2009). A 
satisfactory formulation should involve careful selection of 
excipients, taking into account that supposedly “inert” sub-
stances often interact with APIs (Peres-Filho et al., 2011).
 The efficacy, safety and stability of drugs adminis-
tered in solid oral dosage forms are closely correlated with 
stability, as well as with solubility and permeability prob-
lems (Kommanaboyina, Rhodes, 1999; Murthy, Ghebre-
Sellassie, 1993). Physical factors such as light, heat and 
humidity can trigger or accelerate undesirable chemical 
reactions such as oxidation, hydrolysis, decarboxylation, 
racemization and photolysis, compromising drug stabil-
ity. Oxidation rate is influenced directly by factors such 
as temperature, radiation and pH (Vadas, 2004).
A number of excipients are currently used in oral 
solid technology, most notably those aimed at modulat-
ing the stability of APIs. Antioxidants are introduced 
to improve the shelf life of pharmaceuticals. The term 
oxidation can be defined as the incorporation of oxygen 
into the structure of a drug, or as the process of converting 
one chemical substance into another derivative bearing a 
smaller number of electrons (Smith, March, 2007).
Currently, antioxidants act as efficient excipients 
that delay or inhibit the oxidation of organic and inor-
ganic molecules, preventing the onset and propagation 
of these reactions. This effect however, depends on 
whether their oxidation potentials are higher than those 
of the other components in the formulation (Gülçin et 
al., 2010). Some of the most widely used antioxidants in 
pharmaceutical products and/or the food industry include 
cysteine (CYS) (Kartal et al., 2007), sodium metabi-
sulfite (SMB) (Maia et al., 2007), propyl gallate (PG) 
(Chilson et al., 1950), butylated hydroxytoluene (BHT) 
(Williams et al., 1999) and butylated hydroxyanisole 
(BHA) (Perrin, Meyer, 2002).
These last three antioxidants are polyhydric phe-
nols or derivatives, which exert antioxidant activity by 
supplying electrons or protons labile to free radicals that 
interrupt chain reactions (Wells, 2005). The others listed 
act by undergoing preferential oxidation because of their 
redox potential formulation (Gülçin et al., 2010). Several 
studies have suggested a correlation between the structure 
and activity of antioxidants. However, these reports are 
restricted to phenolic compounds according to the num-
ber of hydroxyl groups, their position in the molecule and 
redox potential (Rosch et al., 2003).
Although widely used as an antioxidant in the 
pharmaceutical and food industries, these excipients 
are associated with numerous adverse reactions such as 
gastric irritation, tumors and more frequently, as a cause 
of colic and diarrhea (Hirose et al., 1997; Okubo et al., 
2004; Williams, Iatropoulos, Whysner, 1999; Williams, 
Iatropoulos, 2004).
Many methods for determining the antioxidant ef-
ficiency of excipients in solution have been published. 
These methods include the Trolox equivalent antioxidant 
activity assay (TEAC assay), the oxygen radical absorbance 
capacity assay (ORAC assay), and the 2,2-diphenyl-1-pic-
rylhydrazyl assay (DPPH radical assay) (Cao, Sofic, Prior, 
1997; Frankel, Meyer, 2000; Rice-Evans, Miller, Paganga, 
1996; Sanchez-Moreno, Larrauri, Saura-Calixto, 1998). The 
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DPPH method is a widely used test because it is simple, fast 
and reproducible (Frankel, Meyer, 2000; Rosch et al., 2003).
One approach used in the present study to evaluate 
the efficiency of antioxidant substances was the DPPH 
test (Rufino et al., 2007). This study was conducted to as-
sess the rational use of BHA, BHT, SMB, PG and CYS in 
tablet formulations of simvastatin (Srinivasu, Raju, Reddy, 
2002) (Figure 1) - widely used in hyperlipidemia treatment 
- and of ketoconazole (Figure 2) - an imidazole deriva-
tive used in the treatment of fungal infections (Viçosa et 
al., 2009). These antioxidants were evaluated according 
to stability parameters and the relationship between the 
efficiency of the antioxidant and chemical structure of 
the drugs. Moreover, the results obtained were compared 
with those of DPPH tests conducted on the same excipient 
concentrations and computational simulations in order to 
achieve more rational use of this class of substances.
Stability studies can guide the search for solutions 
that minimize or delay the processes of degradation. 
Therefore, the ability to predict oxidation reactions in 
different drugs becomes extremely important.
Establishing a correlation among antioxidant activity 
on tests in solution, computer simulations and via concomi-
tant application of these excipients in solid oral formula-
tions, would represent a valuable tool for predicting the 
efficiency of the class of antioxidants and for rationalizing 
use in the technology of pharmaceutical formulations.
Thus, the aim of this work was to perform a study 
investigating different antioxidants’ activity in solution 
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FIGURE 1 - Chemical structure of simvastatin.
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FIGURE 2 - Chemical structure of ketoconazole.
using the DPPH test, computer simulations, and in solid 
oral formulations with different drugs by conducting sta-
bility studies in a bid to rationalize their use in different 
formulations. This correlation method is a novel approach 
introduced by the present manuscript.
MATERIAL AND METHODS
Chemicals and solutions
Glacial acetic acid, sodium lauryl sulfate and potas-
sium phosphate monobasic were purchased from Merck 
(Merck & Co., Darmstadt, Germany). The antioxidants 
(BHA, BHT, SMB, PG and CYS) were obtained from 
Sigma-Aldrich® (Sigma-Aldrich Corporation St. Louis, 
United States). Microcrystalline cellulose PH 102 (Avicel® 
PF – 102) and croscarmellose sodium (Acdisol®) were 
purchased from FMC Biopolymer (Philadelphia, USA). 
Colloidal silicon dioxide, magnesium stearate and spray 
dried monohydrate lactose were supplied by Wyndale® 
(Hawera, NZ). Simvastatin and ketoconazole were pro-
vided by Sigma-Aldrich® (Sigma-Aldrich Corporation St. 
Louis, United States). Drug standards (simvastatin and 
ketoconazole) were obtained from the USP 34 monograph 
general chapter (USP, 2011). All other chemicals were of 
analytical grade.
Tablet production
The quality of all raw materials used in tablet produc-
tion was determined using the USP 34 monograph general 
chapter (USP, 2011). Cylindrical simvastatin tablets (S1 and 
S2) based on the Zocor® formulation containing BHT (as 
described in Table I) were produced by direct compression 
using a punch tableting machine (Erweka, Heusenstamm, 
Germany). Tablets based on the S2 formulation were then 
produced containing BHA, CYS, PG or SMB at a concen-
tration of 0.9%. The resulting tablets were used to dem-
onstrate the most effective of the studied excipients. The 
chosen antioxidant was then used at concentrations ranging 
from 0.05 to 0.9%. Cylindrical ketoconazole tablets (K1 and 
K2) were produced by direct compression using the formu-
lation given (International Conference on Harmonization, 
2003) in Table II, adding the most effective antioxidant for 
the simvastatin formulation and SMB (traditionally used 
for this drug), respectively.
Tablet characterization
Physical characterization
Tablet characterization was done in accordance 
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with the USP 34 monograph general chapter (USP, 2011), 
observing sample friability (friabilometer NT 240 Nova 
Ética, Brazil), weight (analytical balance AG-204 Met-
tler Toledo, Brazil), hardness (hardness tester 298-ATTS 
Nova Ética, Brazil), and disintegration in water at 37 °C 
(tablet disintegrator 301-AC Nova Ética, Brazil). Sample 
friability and hardness were calculated as the mean of 
ten determinations, sample weight as the mean of twenty 
determinations, and disintegration time as the mean of six 
determinations.
Chemical characterization
Content uniformity of the tablets was determined in 
accordance with the USP 34 monograph general chapter 
(USP, 2011), by UV detector (UV-Vis spectrophotometer 
L-4250, Shimadzu Co.Ltd., Kyoto, Japan) set at 238 nm 
for simvastatin, and 225 nm for ketoconazole.
Simvastatin content
The content was as described in the USP 34 mono-
graph for simvastatin tablets (USP, 2011). Chromato-
graphic separations were carried out with a C18 (4.6 mm x 
25 cm) column containing L1 packing, using acetonitrile 
and a phosphoric buffer solution with pH 4.5 (65:35) as 
the mobile phase. Injection volumes were 10 µL for all 
simvastatin tablet samples at a flow rate of 1.5 mL.min-1 
at 45 ºC. The UV detector was set at 238 nm. Sample and 
standard solutions were prepared using an acetic acid 3.0% 
aqueous solution with pH 4.0: acetonitrile (20:80).
Ketoconazole content
The content test was performed as described in the 
USP 34 monograph for ketoconazole tablets (USP, 2011). 
Analyses were carried out with a C18 (3.9 mm x 30 cm) col-
umn containing L1 packing, using a mixture of diisopro-
TABLE I – Formulation of simvastatin tablets S1 and S2
S1 S2
UQa P (%)b UQa P (%)b
Simvastatin 20.0 20.0 20.0 20.0
Spray-dried monohydrate lactose 37.4 37.4 * *
Croscarmellose sodium 1.0 1.0 3.0 3.0
Microcrystalline cellulose PH 102 39.0 39.0 74.6 74.6
Colloidal silicon dioxide 1.0 1.0 1.0 1.0
BHTc 0.9 0.9 0.9 0.9
Magnesium stearate 0.7 0.7 0.5 0.5
Total 100.0 100.0 100.0 100.0
a unitary quantity; b percentage; c butylated hydroxytoluene.
* Absent in formulation.
TABLE II – Formulation of ketoconazole tablets K1 and K2
K1 K2
UQa P (%)b UQa P (%)b
Ketoconazole 200 42.5 200 42.5
Spray-dried monohydrate lactose 225.0 47.9 225.0 47.9
Croscarmellose sodium 15 3.2 15 3.2
Microcrystalline cellulose PH 102 25 5.3 25 5.3
Colloidal silicon dioxide 2.5 0.53 2.5 0.53
BHTc 0.47 0.1 * *
SMBd * * 0.47 0.1
Magnesium stearate 2.5 0.53 2.5 0.53
Total 470 100 470 100
a unitary quantity; b percentage; c butylated hydroxytoluene; d sodium metabisulphite. 
* Absent in formulation
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pylamine in methanol (1 in 500) and ammonium acetate 
solution (1 in 200) (70:30) as the mobile phase. Injection 
volumes were 20 µL with a flow rate of 2.0 mL.min-1 at 
room temperature. The UV detector was set at 225 nm. 
The samples and standard were diluted using a mixture 
of methanol and methylene chloride (50:50).
Dissolution study
Simvastatin tablet dissolution
Dissolution studies of simvastatin tablets were 
performed using the rotating-paddle method (Hanson 
Research, SR8 8-Flask Bath, Ontario, Canada) for 30 
minutes, at 50 rpm. A volume of 900 mL of dissolution 
medium was used, which consisted of sodium phosphate 
buffer 0.01 M pH 7.0 containing 0.5% sodium dodecyl 
sulfate according to the procedure described in the USP 34 
monograph for this tablet (USP, 2011). After 30 minutes, 
the aliquot was filtered through a 0.45 µm filter and trans-
ferred to a centrifuge tube containing approximately 10 mg 
of prewashed manganese dioxide per 1 mL of transferred 
solution under test. These mixtures were maintained under 
stirring for 30 minutes and centrifuged. Samples, standard 
and blank absorbance were then measured at 238 nm in a 
spectrophotometer (UV-Vis spectrophotometer L-4250, 
Shimadzu Co.Ltd., Kyoto, Japan).
Ketoconazole tablet dissolution
Dissolution studies of ketoconazole tablets were per-
formed using the rotating-paddle method, according to the 
procedure described in the USP 34 monograph for this tab-
let (USP, 2011). Dissolution was carried out for 30 minutes 
at 50 rpm with 900 mL of 0.1 N hydrochloric acid. After 
30 minutes, samples were filtered through a 0.45 µm filter 
and diluted with dissolution medium. Samples, standard 
and blank absorbance were then measured at 225 nm in a 
spectrophotometer (UV-Vis spectrophotometer L-4250, 
Shimadzu Co.Ltd., Kyoto, Japan).
Stability study
The accelerated stability study of all the tablet 
formulations produced was performed at 40°C ± 2ºC 
and 75% ± 5% relative humidity, at sampling times of 0, 
3 and 6 months (Brasil, 2005), denoted T0, T1 and T2, 
respectively (stability chambers, 420/CLD Nova Ética, 
São Paulo, Brazil). Content and dissolution studies were 
conducted at each timepoint.
DPPH antioxidant activity assay
Determination of the antioxidant capacity of the 
studied excipients was performed using an adapted DPPH 
method (Rufino et al., 2007). Initially, stock solutions 
of methanol:water (50:50), acetone:water (70:30) were 
prepared, as well as a control solution of methanol and 
acetone stock solutions mixed with water (40:40:20). A 
0.06 mM DPPH radical standard solution was prepared 
in methanol for the analysis of BHA, BHT, CYS and PG, 
and in distilled water for analysis of SMB. The sample 
solutions (1.0 mg/mL) were prepared in methanol or dis-
tilled water, respectively. A 3.9 mL volume of the standard 
solution, 0.1 mL of the sample solution and 0.1 mL of the 
control solution, were added to an assay tube. Methanol or 
water was used as a blank. The reaction was performed in 
the dark at room temperature, and the analyses were con-
ducted using a spectrophotometer measuring absorbance 
reduction at 515 nm. The DPPH calibration curve was 
prepared using the initial standard solution at concentra-
tions ranging from 10 to 60 mM.
Molecular modeling studies
Molecular modeling was performed using SPAR-
TAN’09 software (Wavefunction Inc. Irvine, CA, 2000. 
Using this software, structures were minimized and 
the equilibrium geometry obtained in a vacuum using 
a semi-empirical AM1 module (Rocha et al., 2006). In 
order to evaluate the electronic properties of the AM1 
minimal energy conformations, they were submitted to 
a single-point calculation using the density functional 
theory (DFT) method, B3LYP functional and the 6-31G* 
basis set of SPARTAN’09. The electronic properties in-
cluding HOMO (Highest Occupied Molecular Orbital) 
and LUMO (Lowest Unoccupied Molecular Orbital) 
energies and density, coefficient distribution, GAP (dif-
ference between HOMO and LUMO orbitals), absolute 
hardness (η, correlated to the amount of energy needed 
for the transition of an electron from the HOMO to the 
LUMO orbitals) (Arroio, Honório, Silva, 2010) and di-
pole moment vector, were calculated for all compounds. 
Molecular electrostatic potential isoenergy surface maps 
were also generated with a range of energies from - 25 
(deepest red) to 30 (deepest blue) kcal/mol and superim-
posed onto a surface having a constant electron density 
of 0.002e/au3.
RESULTS AND DISCUSSION
Tablet production and characterization
The raw materials were analyzed, yielding 99.40% 
content for simvastatin without the presence of lovastatin, 
considered an impurity, and 98.15% for ketoconazole 
(Bertacche et al., 2007; Markman, Rosa, Koschtschak, 
M. T. Celestino, U. O. Magalhães, A. G. M. Fraga, F. A. Carmo, V. Lione, H. C. Castro, V. P. Sousa, C. R. Rodrigues, L. M. Cabral410
2010).
The proposed formulations of the tablets were 
produced (S1 and S2) based on the Zocor® formulation, 
showing difference in the presence of lactose in S1 (as in 
Zocor® formulation) and increased croscarmellose sodium 
and microcrystalline cellulose PH 102 concentrations in 
S2, with lactose removal. The ketoconazole tablets were 
produced using a previous formulation developed by our 
research group (Viçosa et al., 2009).
Sample weight, friability, hardness, disintegration, 
dissolution and content uniformity for all the simvastatin 
and ketoconazole tablets produced (data not shown) were 
in accordance with the USP 34 monograph general chapter 
(USP, 2011).
For the simvastatin tablets, the characterization 
tests demonstrated that the absence of lactose allowed 
for higher flux, lower adherence to the top punches of the 
compressor machine and greater reproducibility of results 
for hardness and sample weight, resulting in differences 
between formulations. Also, the increased proportion of 
croscarmellose sodium, a disintegrant excipient, in the S2 
formulation from 1.0 to 3.0% contributed to increased dis-
integration of the tablet and release of the API, as expected. 
Initially, the improvement in the dissolution rate of the S2 
formulation compared to S1 was around 6% (p = 0.0038).
The improvement in dissolution rate of the S2 for-
mulation compared to S1 could be attributed to the use of 
a soluble solvent possessing reducing properties (Pifferi, 
Santoro, Pedrani, 1999). The addition of a larger propor-
tion of directly compressed microcrystalline cellulose PH 
102 may lead to more efficient disintegration, enhancing 
the dissolution of the active simvastatin (Shirzad, Roa, 
Raimar, 2007).
After the production of S1 and S2 formulations, the 
dissolution profile and the tableting process were used as 
factors for selecting the optimal formulation. Therefore, 
S2 was considered more technically favorable than S1 for 
tablet production. However, since lactose was used, this 
behavior would not normally be expected, specifically 
for the direct compression processes (lactose α-spray 
dryer) (Prista, Alves, Morgado, 2002). This suggests a 
possible interaction between simvastatin and lactose. The 
use of lactose as an excipient for direct compression can 
sometimes result in drug – excipient incompatibility, as 
observed in the Maillard reaction (Bharate, Bharate, Bajaj, 
2010). Apart from the lactose factor, greater croscarmel-
lose sodium in the formulation was observed, which also 
contributed to the disintegration of the tablet and release 
of the active ingredient.
The S2 formulation was considered more appropri-
ate and therefore used as a prototype for the others to be 
studied. The ketoconazole tablets were produced without 
any technical problems.
DPPH antioxidant activity assay
The antioxidant activity of the selected excipients 
(BHA, BHT, SMB, PG and CYS) was evaluated by a 
method adapted from DPPH (Rufino et al., 2007). The 
DPPH calibration curve obtained was linear with a cor-
relation coefficient of 0.9977. The analysis shown in 
Table III reveals that the largest percentage reduction of 
absorbance was observed for PG, while SMB proved to 
be most efficient, with only 6.47% reduction and lower 
consumption of DPPH.
The same pattern was observed, albeit with lower 
efficiency, for all the other lipophilic antioxidants such as 
BHT and BHA, indicating a relationship between solva-
tion effect and efficacy of the excipient. This indicates that 
the greater polarizability of the molecule showed higher 
electronic stabilization and solvation effects during its 
transition state, resulting in higher efficiency in solution. 
TABLE III – Comparative evaluation of antioxidant activity with DPPH
Antioxidant
Initial 
absorbance ± 
r.s.d.*
Final 
absorbance ± 
r.s.d.*
Control 
absorbance
Relative 
percentage of 
absorbance 
reduction
Solvent
Time for 
stabilization 
(min)
CYSa 0.642±0.046 0.275±0.017 0.701 57.16 methanol 120
PGb 0.383±0.082 0.004±0.00013 0.702 98.95 methanol 2
SMBc 0.603±0.035 0.564±0.070 0.701 6.47 water 60
BHAd 0.570±0.028 0.119±0.009 0.701 79.12 methanol 60
BHTe 0.606±0.022 0.139±0.0071 0.701 77.06 methanol 160
a cysteine; b propyl gallate; c sodium metabisulfite; d butylated hydroxyanisole; e butylated hydroxytoluene.
* relative standard deviation.
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TABLE IV – Stability study of S2 formulation with different antioxidants
T0 T1 T2
BHTa 0.9% Content (%) ± r.s.d.* 98.2 ± 1.6 89.3 ± 2.4 88.2 ± 0.9
Dissolution (%) ± r.s.d.* 86.2 ± 3.8 82.0 ± 5.1 77.4 ± 5.0
PGb 0.9% Content (%) ± r.s.d.* 92.2 ± 1.3 88.6 ± 2.5 80.6 ± 1.2
Dissolution (%) ± r.s.d.* 82.5 ± 5.4 77.5 ± 5.0 72.4 ± 6.9
BHAc 0.9% Content (%) ± r.s.d.* 94.3 ± 0.4 89.2 ± 3.0 83.2 ± 1.8
Dissolution (%) ± r.s.d.* 82.6 ± 4.9 75.3 ± 5.3 70.0 ± 5.1
CYSd 0.9% Content (%) ± r.s.d.* 95.2 ± 1.4 86.8 ± 1.1 63.5 ± 3.2
Dissolution (%) ± r.s.d.* 83.2 ± 6.0 79.8 ± 5.2 54.8 ± 7.0
SMBe 0.9% Content (%) ± r.s.d.* 93.5 ± 1.2 81.4 ± 2.2 71.8 ± 1.2
Dissolution (%) ± r.s.d.* 84.4 ± 3.6 72.3 ± 4.5 68.3 ± 4.3
a butylated hydroxytoluene; b propyl gallate; c butylated hydroxyanisole; d cysteine; e sodium metabisulfite.
* relative standard deviation.
These results raise the question as to whether the same 
holds true for the solid phase (Barclay et al., 1990).
Stability study
During the stability study, it is important to verify 
both drug content and dissolution rate at all sampling times 
because the drug can degrade, for example by oxidation, 
reducing the content, while degradation products can 
influence dissolution rate (International Conference on 
Harmonization, 2003; Brasil, 2005).
The antioxidants BHA, BHT, CYS, PG or SMB 
were included in the S2 formulation at 0.9% to determine 
which was most efficient in terms of drug stability and 
the most efficient solid phase antioxidant. According to 
the results obtained in the accelerated stability study of 
these formulations (Table IV), BHT was the most efficient 
regarding simvastatin stability, exhibiting around 10% 
content variation. The content of the formulations with 
PG, BHA, CYS and SMB had variations of approximately 
11.6, 11.1, 31.7 and 21.7%, respectively. In contrast to 
the behavior observed in solution, CYS and SMB were 
the least efficient in solid phase among all antioxidants 
studied. BHA and PG proved to be statistically similar in 
terms of content maintenance (p = 0.0789).
Due to its efficiency in controlling the content of 
this drug, in comparison with other antioxidants, the 
other formulations were produced using BHT at con-
centrations of 0.05, 0.1, 0.5 and 0.9% (Table V). The 
most effective concentrations of BHT in terms of low-
est content, dissolution variations, and maintaining the 
stability of simvastatin, were 0.5 and 0.1%. Thus, the 
lowest concentration was chosen as optimal for the case 
of simvastatin, avoiding side effects and reducing costs. 
The extreme values of 0.05% and 0.9% were less efficient 
in terms of maintaining the content and dissolution of 
pharmacotechnical ingredients. All results differed statis-
tically in terms of the content of simvastatin (p = 0.0032) 
and dissolution (p=0.0023).
S2 is an uncoated tablet and highly stable when BHT 
0.1% was used, proving that a coating is not essential for 
maintaining drug stability of simvastatin formulations. 
Zocor® is a coated tablet which has a higher antioxidant 
concentration than S2, making this reference drug more 
susceptible to the occurrence of side effects with an inher-
ently more expensive manufacturing process (Hirose et al., 
1997; Okubo et al., 2004; Williams, Iatropoulos, Whysner, 
1999; Williams, Iatropoulos, 2004).
The inefficiency of SMB in the S2 formulation is in 
contrast to that described in the literature for this excipient 
(Lavoie, Lachance, Chessex, 1994) and to the DPPH as-
say results. A possible explanation may lie in the chemical 
structure of the molecule, which acts to prevent degrada-
tion, or in the oxidation mechanism involved. In the case 
of SMB, capture and stabilization of free radicals was not 
always observed as for BHA or BHT (Brand-Williams, 
Cuvelier, Berset, 1995).
Initially, the mechanism of oxidation of simvastatin 
involves capturing these radical forms, which leads to 
greater efficiency for BHT (Mohamadin et al., 2011). 
However, this hypothesis can only be confirmed by replac-
ing the studied drug. Therefore, in order to elucidate the 
above-mentioned relationship, two different ketoconazole 
tablet formulations were produced (K1 and K2).
SMB, previously used for the production of keto-
conazole tablets (Viçosa et al., 2009) was used at 0.1% in 
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this study; the rationalized concentration in previous tests 
with simvastatin.
Two different ketoconazole tablet formulations were 
produced (K1 and K2). The results of accelerated stability 
studies for these tablets are given in Table VI. According 
to the results, SMB was most efficient at maintaining the 
content and dissolution profile for this drug.
A strong relationship between drug structure and 
antioxidant efficiency was observed. This relationship was 
evidenced by the stability studies of ketoconazole tablets, 
where BHT, the most efficient antioxidant for simvastatin 
tablets, presented a higher variation in content between the 
start and end of the test when compared to SMB. The disso-
lution values changed only slightly over a six-month period 
for both formulations, remaining above the 80% required 
by the USP 34 monograph general chapter (USP, 2011).
Molecular modeling studies
Several molecular electronic parameters were calcu-
lated for the antioxidants BHA, BHT, CYS, SMB and PG 
(dipole moment, cLogP and energy of HOMO and LUMO 
orbitals) and compared with antioxidant activity. Overall, 
no clear or direct correlation was observed for most of the 
parameters evaluated except for the orbitals HOMO and 
LUMO and for the analysis of the 3-D structures. (Figure 
3 and Table VII). Higher values  of EHOMO were observed 
for SMB, BHA, BHT, PG and CYS indicating a better 
antioxidant profile for SMB, BHA and BHT, supporting 
the results of studies in solid phase (tablet stability).
The effects of hydrogen bonds between methanol or 
other polar protic solvent and phenolic antioxidants can 
also lead to a reduction in their activity (Ghose, Pritchett, 
Crippen, 1988). In this initial evaluation, CYS and SMB 
were chosen as the most effective antioxidants. These re-
sults were confirmed by the values of cLogP calculated by 
molecular modeling using the method of Ghose-Pritchett-
Crippen (Ghose, Pritchett, Crippen, 1988) showing the 
influence of lipid solubility on antioxidant activity.
Moreover, the values of GAP and absolute hardness 
were in agreement with the results obtained on the DPPH 
assay, demonstrating that antioxidant activity is directly 
related to the hardness and softness of each compound 
when in solution. Thus, the lower GAP value led to greater 
reactivity of the molecule in solution for the radical captur-
ing reaction. Also, the lower the hardness, the lower the 
amount of energy needed for the transition of an electron 
from HOMO to LUMO. In this case, the molecule with the 
highest antioxidant activity in the DPPH assay was SMB 
(η = -1.72 and GAP= -3.44).
TABLE V – Stability study of S2 formulation containing BHT as antioxidant at different concentrations
T0 T1 T2
BHTa 0.9% Content (%) ± r.s.d.* 98.2 ± 1.6 89.3 ± 2.4 88.2 ± 0.9
Dissolution (%) ± r.s.d.* 86.2 ± 3.8 82.0 ± 5.1 77.4 ± 5.0
BHT 0.5% Content (%) ± r.s.d.* 93.5 ± 0.6 90.9 ± 0.5 88.2 ± 1.2
Dissolution (%) ± r.s.d.* 87.4 ± 3.4 83.0 ± 2.8 79.2 ± 5.0
BHT 0.1% Content (%) ± r.s.d.* 94.6 ± 0.5 91,3 ± 0.3 89.3 ± 2.0
Dissolution (%) ± r.s.d.* 85.2 ± 2.4 82.0 ± 4.5 77.4 ± 5.5
BHT 0.05% Content (%) ± r.s.d.* 95.9 ± 0.2 92.9 ± 0.6 85.6 ± 1.2
Dissolution (%) ± r.s.d.* 85.4 ± 4.7 81.0 ± 4.0 78.7 ± 3.6
a butylated hydroxytoluene.
* relative standard deviation.
TABLE VI – Stability study of K1 and K2 tablet formulations
T0 T1 T2
BHTa 0.1% Content (%) ± r.s.d.* 98.1 ± 0.3 83.6 ± 0.3 69.7 ± 1.5
Dissolution (%) ± r.s.d.* 89.0 ± 3.2 83.5 ± 3.7 83.9 ± 4.6
SMBb 0.1% Content (%) ± r.s.d.* 99.7 ± 0.5 98.5 ± 1.2 97.7 ± 1.9 
Dissolution (%) ± r.s.d.* 88.3 ± 4.5 86.4 ± 3.7 85.9 ± 3.5
a butylated hydroxytoluene; b sodium metabisulfite.
* relative standard deviation.
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TABLE VII – Theoretical properties of tested antioxidants
ANTIOXIDANT EHOMOa ELUMOb GAP(H-L)c ηd cLogPe
BHTf -5.73 0.26 -5.99 -2.99 5.54
BHAg -5.12 0.18 -5.30 -2.65 3.22
CYSh -6.31 -0.18 -6.13 -3.06 -0.92
PGi -5.88 -0.89 -4.99 -2.49 1.51
SMBj -3.39 0.13 -3.44 -1.72 -1.35
a HOMO energy; b LUMO energy; c Gap: difference between HOMO and LUMO orbitals; d absolute hardness; e partition coefficient 
calculated by the Ghose-Pritchett-Crippen method; f butylated hydroxytoluene g butylated hydroxyanisole; h cysteine; i propyl 
gallate; j sodium metabisulfite.
The results of this study showed that theoretical pa-
rameters obtained by molecular modeling were correlated 
with antioxidant activity in solution, being useful for the 
rational development of liquid pharmaceutical formula-
FIGURE 3 - 3D representation for antioxidants BHA, BHT, CYS 
and PG respectively. HOMO (A) densities encoded onto a van 
der Waals surface (isodensity 0.002 e/au3), the orbital absolute 
density HOMO coefficient (B) was mapped from deepest red 
(0.00) to deepest blue (0.01).
tions but not for solid oral formulations.
CONCLUSIONS
In conclusion, the results of the present study 
showed that it is not possible to rationalize the use of 
antioxidants in solid formulations. The results revealed 
inefficiency of SMB in the S2 formulation, in contrast 
to behavior described in the literature for this excipient.
However, the use of antioxidants in solution (DPPH 
and molecular modeling) were in agreement, showing a 
rational correlation with antioxidant activity in solution, 
being a useful tool for the rational development of liquid 
pharmaceutical formulations.
In addition, the use of different excipients in the 
formulation of tablets influences both functionality and 
choice of antioxidants.
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